Combined Research

 
Stock Quotes for Combined Research top ^
  • Industry: Rubber & Plastics
  • Sector: Consumer Cyclical
  • Stock Style: Small Value
Sign-up for n0z investment picks

 
News Articles for Combined Research top ^
2014/10/23
2014 Operating Income per Share Guidance Is Increased To Range of $7.35 to $7.45 WARREN, N.J. , Oct.
Sign-up for Chubb Reports Third Quarter Net Income per Share of $2.47; Operating Income per Share Is a Record $2.17; Combined Ratio Is 85.8% investment picks
ACE Limited (NYSE: ACE) today reported net income for the quarter ended September 30, 2014, of $2.32 per share, compared with $2.66 per share for the same quarter last year.
Sign-up for ACE Reports Record Quarterly Operating Income of $2.64 Per Share, up 6%; Global P&C Net Premiums up 4%; P&C Combined Ratio is 86.3% and Operating Return on Equity is 12.6% investment picks
Scorpio Mining and U.S. Silver & Gold Announce Business Combination to Create a Well-Funded Junior Silver Producer Canada NewsWire TORONTO , Nov.
Sign-up for Scorpio Mining and U.S. Silver & Gold Announce Business Combination to Create a Well-Funded Junior Silver Producer investment picks
Halliburton Company (NYSE:HAL) and Baker Hughes Incorporated (NYSE:BHI) today announced a definitive agreement under which Halliburton will acquire all the outstanding shares of Baker Hughes in a stock and cash transaction.
Sign-up for Halliburton and Baker Hughes Reach Agreement to Combine in Stock and Cash Transaction Valued at $34.6 Billion investment picks
EMC Insurance Group Inc. (NASDAQ:EMCI) (the “Company”) today announced that third quarter 2014 operating results were impacted by a higher than anticipated level of losses.
Sign-up for EMC Insurance Group Inc. Announces Third Quarter Operating Income and Combined Ratio Estimates and Revises 2014 Operating Income Guidance investment picks
2014/10/30
Combined Entity to be Named Zimmer Biomet WARSAW, Ind.
Sign-up for Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0979390001&sourceType=1 http://media3.marketwire.com/logos/20140725-OSK_logo_200.jpg http://www.ccnmatthews.com/logos2/virginia.jpg MONTREAL AND QUEBEC CITY, QUEBEC --
Sign-up for Osisko and Virginia Announce Business Combination to Create a Leading Intermediate Gold Royalty Company investment picks
Clearance Completes Required Regulatory Approvals and Confirms Transaction's Expedited Timetable CHARLOTTE, N.C. and DUBLIN, Ireland, Oct.
Sign-up for Chiquita and Fyffes Receive Clearance From the European Commission for Proposed Combination investment picks
100% of evaluable CLL/SLL patients (9/9) had nodal reductions, with 6 of 9 patients achieving a PR with the remaining 3 patients on study with nodal reductions ranging from 15% to 45% and a peripheral response (normalization or >50% decrease in ALC) pending additional assessments 83% (5/6) of patients with Non-Hodgkin's Lymphoma; 3/3 DLBCL and 2/3 Follicular Lymphoma (FL) responded to the combination at the highest dose tested, including 2 CR's in patients with DLBCL confirmed by independent review Collectively, 87 patients have been treated with TGR-1202, alone or in combination with TG-1101, without the observance of drug-related hepatic toxicity Dose escalation continues with TGR-1202 at 800mg micronized The combination of TG-1101, TGR-1202, and ibrutinib ("Triple Therapy") was safely administered to 5 patients with heavily pre-treated NHL, CLL, and Richter's transformation with no dose limiting toxicities observed, and no Grade 3 or 4 events observed to
Sign-up for Preliminary Data From Ongoing Phase I/II Dose Escalation Study of TG-1101 (Ublituximab) in Combination With TGR-1202 in Heavily Pre-treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity and Safety investment picks
Quartet Merger Corp.
Sign-up for Quartet Merger Corp. Completes Business Combination with Pangaea Logistics Solutions Ltd. investment picks
Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced that shareholders of the Nuveen Global Income Opportunities Fund (NYSE: JGG ) and Nuveen Diversified Currency Opportunities Fund (NYSE: JGT ) have approved a proposal to both combine and restructure the funds.
Sign-up for Nuveen Global Income Closed-End Funds Announce Shareholder Approval of Combination and Restructuring investment picks
2014/10/1
This Phase I trial will test the safety and tolerability of lirilumab (BMS-986015) in combination with elotuzumab (BMS-901608) in patients with multiple myeloma This new Phase I initiated by Bristol-Myers Squibb is the first combination trial of lirilumab in a hematological tumor type MARSEILLE, France, Oct.
Sign-up for INNATE PHARMA : INITIATION OF A PHASE I CLINICAL TRIAL OF LIRILUMAB IN COMBINATION WITH ELOTUZUMAB investment picks
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today reviewed recent progress and announced upcoming milestones in its efforts to develop multiple combinations of medicines that treat the underlying cause of cystic fibrosis (CF) for the majority of people with the disease.
Sign-up for Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis investment picks
The Andersons to Combine Turf & Specialty and Plant Nutrient Groups Canada NewsWire MAUMEE, Ohio , Nov.
Sign-up for The Andersons to Combine Turf & Specialty and Plant Nutrient Groups investment picks
BUFFALO, N.Y., Sept.
Sign-up for First Niagara to Combine Consumer Banking Businesses investment picks
2014/9/24
http://media.marketwire.com/attachments/201310/197574_GE_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1146910&ProfileId=051205&sourceType=1 DALLAS, TX --
Sign-up for New GE Power Express Remote Combiner Powers "Small-Cell" Telecommunications and Distributed Antenna System Networks investment picks
2014/9/22
NEW YORK , Sept.
Sign-up for Delta Advanced Materials Limited Completes Business Combination With CIS Acquisition Ltd. investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B) inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
Sign-up for Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting® investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Combined Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Combined Ratio  |  Next: Comerica Bank